Potassium Citrate Tablet, Extended Release
NDC Package 0591-2682-00

11-digit billing NDC: 00591268200

Package Information

Potassium Citrate tablets is potassium citrate is contraindicated:In patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. This formulation utilizes a tablet, extended release delivery system. Marketed by Actavis Pharma, Inc., this product is identified by NDC 0591-2682 and is authorized under FDA application ANDA209758.

Identification & Billing

NDC Package Code
0591-2682-00
Package Description
7825 TABLET, EXTENDED RELEASE in 1 DRUM
Product Code
11-Digit Billing Format
00591268200
RxNorm Crosswalk
  • RxCUI: 199376 - potassium citrate 5 MEQ Extended Release Oral Tablet
  • RxCUI: 199376 - K+ citrate 5 MEQ Extended Release Oral Tablet
  • RxCUI: 199376 - Pot citrate 5 MEQ Extended Release Oral Tablet
  • RxCUI: 199376 - potassium citrate 540 MG Extended Release Oral Tablet
  • RxCUI: 199381 - potassium citrate 10 MEQ Extended Release Oral Tablet

Clinical Specifications

Proprietary Name
Potassium Citrate
Non-Proprietary Name
Potassium Citrate
Substance Name
Potassium Citrate
Dosage Form
Tablet, Extended Release - A solid dosage form containing a drug which allows at least a reduction in dosing frequency as compared to that drug presented in conventional dosage form.
Administration Route
Oral - Administration to or by way of the mouth.
Usage Information
Potassium citrate is contraindicated:In patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. Such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown or the administration of a potassium-sparing agent (such as triamterene, spironolactone or amiloride).In patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract, such as those suffering from delayed gastric emptying, esophageal compression, intestinal obstruction or stricture, or those taking anticholinergic medication.In patients with peptic ulcer disease because of its ulcerogenic potential.In patients with active urinary tract infection (with either urea-splitting or other organisms, in association with either calcium or struvite stones). The ability of potassium citrate to increase urinary citrate may be attenuated by bacterial enzymatic degradation of citrate. Moreover, the rise in urinary pH resulting from potassium citrate therapy might promote further bacterial growth.In patients with renal insufficiency (glomerular filtration rate of less than 0.7 mL/kg/min), because of the danger of soft tissue calcification and increased risk for the development of hyperkalemia.

Regulatory & Marketing

Labeler Name
Actavis Pharma, Inc.
Product Type
Human Prescription Drug
FDA Application #
ANDA209758
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
05-30-2018
End Marketing Date
06-30-2027
Exclude Flag
N
Sample Package
N/A

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (0591-2682). Click a package code to view its specific billing and regulatory data.

100 TABLET, EXTENDED RELEASE in 1 BOTTLE
18780 TABLET, EXTENDED RELEASE in 1 CONTAINER

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0591-2682-00 identifies a specific commercial package of 7825 tablet, extended release in 1 drum of Potassium Citrate, a human prescription drug labeled by Actavis Pharma, Inc.. This tablet, extended release is formulated for oral use and contains potassium citrate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Actavis Pharma, Inc. on May 30, 2018.

How is this Actavis Pharma, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00591268200. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0591-2682-00
11-Digit CMS (5-4-2)
00591-2682-00

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.